RESUMEN
Objective To observe the change of the serum ABCG2 level of patients with non‐small cell lung cancer(NSCLC)be‐fore and after chemotherapy ,and explore its clinical significance .Methods Venous blood specimens of 15 healthy adults and 50 pa‐tients with NSCLC were collected before and chemotherapy ,the serum ABCG2 level of these specimens were detected by ELISA . the relation between the ABCG2 level and the chemosensitivity was investigated .Results The serum ABCG2 level of patients with NSCLC before chemotherapy was significantly higher than that in healthy adults(P0 .05);among chemoresistant patients ,the serum ABCG2 level of patients with NSCLC after chemotherapy was significantly higher than that of before(P0 .05) .Conclusion The serum ABCG2 level of patients with NSCLC is higher than that of healthy adults ;serum ABCG2 level may become a useful indicator in predicting the effect of NSCLC chemotherapy .
RESUMEN
<p><b>BACKGROUND</b>Ku70, Ku80 and DNA-PKcs proteins take part in the repairment of DNA double-strand breaks as regulatory subunits of DNA-dependent protein kinase. The aim of this study is to investigate the expression and clinical significance of Ku70, Ku80 and DNA-PKcs proteins in patients with stage I-II non-small cell lung cancer (NSCLC).</p><p><b>METHODS</b>A total of 86 patients with stage I-II NSCLC who received adjuvant chemotherapy after radical surgery were retrospectively analyzed. The expression of Ku70, Ku80 and DNA-PKcs proteins was detected by tissue microarray technique and immunohistochemical two-step method.</p><p><b>RESULTS</b>The positive rate of Ku70, Ku80 and DNA-PKcs in lung cancer tissues was 68.6%, 72.1% and 87.2%, respectively. Their expression was not related to histological classification (P > 0.05). The patients with worse prognosis seemed to have higher expression of Ku70, Ku80 and DNA-PKcs proteins, however there was no statistical significance (P > 0.05).</p><p><b>CONCLUSIONS</b>Ku70, Ku80 and DNA-PKcs are overexpressed in stage I-II lung cancer without prior chemotherapy. They may be not good for guidance of postoperative chemotherapy in completely resected stageI-II NSCLC.</p>
RESUMEN
<p><b>BACKGROUND</b>To maximize the preservation of functional pulmonary parenchyma and improve the quality of life of patients with centrally located lung cancer, trachea-bronchoplasty has been used in clinical application with good efficacy. The aim of this study is to explore the appropriate admission and management of trachea-bronchoplasty and prevent complications of trachea-bronchial sleeve resection in the treatment of centrally located lung cancer.</p><p><b>METHODS</b>Seventy-six patients with central lung cancer, who were treated with trachea-bronchoplasty from June, 1988 to October, 2004, were analyzed. There were 49 cases of squamous cell carcinoma, 16 adenocarcinoma, 7 adenosquamous carcinoma, 3 small cell lung cancer and 1 adenoid cystic adenocarcinoma. Seventeen patients were in stage I, 39 in stage II, 17 in stage IIIA and 3 in stage IIIB. There were 55 cases of sleeve lobectomy, 12 lobectomy with wedge resection of the main bronchus, 8 big arc resection of superior lobar bronchus-main trachea-lateral wall of trachea, 1 resection of right upper lobe-right main bronchus-carina-lateral trachea and carinal reconstruction.</p><p><b>RESULTS</b>Postoperative complications happened in 7 patients. Pneumonia and atelectasis occurred in 6 cases, in which 1 died of heart and respiratory failure. Another one died of haemorrhage of upside alimentary canal. Seventy-one patients were followed up (93.4%). The 1-, 3-, 5-year survival rate was 82.4% (56/68), 57.8% (26/45) and 41.7% (15/36) respectively.</p><p><b>CONCLUSIONS</b>The trachea-bronchoplasty can not only preserve functional pulmonary parenchyma as much as possible and improve the quality of life of patients, but also provide an operative opportunity to those patients with poor pulmonary function in the treatment of centrally located lung cancer.</p>